Rad51-dependent Homologous Recombination Restoration and Parp Inhibitor Resistance in Brca-mutated Ovarian Cancer: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies — an Umbrella Review
Year: 2026
Type: article
Abstract: Background: Poly (ADP-ribose) polymerase inhibitors exploit synthetic lethality in homologous recombination-deficient ovarian cancer, particularly in carcinomas harboring pathogenic BRCA alterations. However, resistance frequently emerges when DNA repair capacity or replication-fork stability is restored. The functional recovery of homologous recombination mediated by the recombinase RAD51 represents a central mechanism underlying therapeutic failure. Methods: In this umbrella review, four clinical systematic reviews and meta-analyses were synthesized to evaluate progression-free and overall survival outcomes across molecular strata without de novo pooling due to primary trial overlap. Fifteen translational cohorts were integrated to evaluate secondary BRCA reversion mutations, functional RAD51 foci formation assays, circulating tumor DNA monitoring, and resistance-directed combination strategies. Results: Systematic review evidence confirms substantial progression-free survival benefit from maintenance inhibitor therapy in BRCA-mutated cohorts, with intermediate benefits in homologous recombination-deficient cohorts and attenuated gains in repair-proficient disease. Therapeutic resistance arises through secondary reading-frame reversions in BRCA and RAD51 genes, alteration of 53BP1-shieldin end-resection complexes, stabilization of replication forks by SNF2-family remodelers, and epigenetic reactivation. Functional RAD51 foci assays identify dynamic repair competence across archival specimens, while longitudinal circulating tumor DNA detects emerging resistant clones prior to radiological progression. Early-phase combinations targeting checkpoint kinases demonstrate objective responses in resistant tumors. Conclusion: RAD51-dependent homologous recombination recovery provides a cohesive functional framework for acquired inhibitor failure. Dynamic functional assays and longitudinal liquid biopsies offer essential predictive utility to overcome the limitations of static genomic markers in guiding tailored intervention.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236171082
